Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: chemotherapy, intrathecal chemotherapy Clear all
Completed Phase 3 Interventional Results available

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

NCT00137111
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute
Interventions
Prednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplantation
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Months to 18 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
2
States / cities
Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 9, 2026, 4:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

NCT03793478
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Month to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 9, 2026, 4:53 PM EDT
Recruiting Phase 2 Interventional

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

NCT05519579
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Methotrexate, Blinatumomab
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

NCT00096135
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Months to 29 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
135
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

NCT00058370
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, lomustine, vincristine sulfate, adjuvant therapy, iodine I 131 monoclonal antibody 3F8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

NCT01861002
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
Interventions
Azacytidine, Fludarabine, Cytarabine, Intrathecal (IT) Cytarabine, Intrathecal Methotrexate (IT MTX)
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 9, 2026, 4:53 PM EDT
Terminated Phase 2 Interventional Results available

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

NCT00882206
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
cytarabine, decitabine, doxorubicin hydrochloride, imatinib mesylate, methotrexate, pegaspargase, prednisone, vincristine sulfate, vorinostat
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

NCT02212561
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Mixed Phenotype Acute Leukemia (MPAL)
Interventions
Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Phase 3 Interventional

A Study of Children With Refractory or Relapsed ALL

NCT00187083
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Topotecan, dexamethasone, vincristine, E. coli Asparaginase, PEG-L-asparaginase, erwinia asparaginase, fludarabine, methotrexate, mercaptopurine, idarubicin, etoposide, cytarbine, teniposide, chemotherapy, intrathecal chemotherapy, steroid therapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Oct 9, 2026, 4:53 PM EDT
Recruiting Phase 1 Interventional

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

NCT06376162
View directory record Official record
Conditions
Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
Interventions
Ziftomenib, Cytarabine, Fludarabine
Drug
Lead sponsor
PedAL BCU, LLC
Other
Eligibility
0 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 9, 2026, 4:53 PM EDT
Active, not recruiting Phase 2 Interventional

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

NCT00338377
View directory record Official record
Conditions
Melanoma
Interventions
Dendritic Cell Immunization, Cyclophosphamide, Fludarabine, T-Cells, Interleukin-2, Mesna, Intrathecal T-Cells, Intrathecal Interleukin-2
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 9, 2026, 4:53 PM EDT
Recruiting Early Phase 1 Interventional

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

NCT07059975
View directory record Official record
Conditions
Acute Myeloid Leukemia, Pediatric AML
Interventions
Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 30 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia

NCT00003178
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cladribine, idarubicin
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 9, 2026, 4:53 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT03164057
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, ITMHA, Idarubicin, Fludarabine, Mitoxantrone, Erwinia asparaginase, Sorafenib, G-CSF, Dexrazoxane, Stem Cell Transplant, Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Drug · Combination Product · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
29 Days to 21 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Madera, California • Orange, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 9, 2026, 4:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

NCT05192889
View directory record Official record
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Dasatinib, Cytarabine, Blinatumomab, Methotrexate, Mercaptopurine, Cyclophosphamide, Etoposide, Leucovorin, Intrathecal Triples, Pegaspargase, Erwinia asparaginase, Radiation
Drug · Biological · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
4 Years to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 9, 2026, 4:53 PM EDT
Active, not recruiting Phase 2 Interventional

Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma

NCT03688451
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
Rituximab
Drug
Lead sponsor
Tahir Latif
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 9, 2026, 4:53 PM EDT
Terminated Phase 3 Interventional

Treatment of Childhood Acute Lymphoblastic Leukemia

NCT00165087
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
asparaginase (E. Coli), asparaginase (Erwina), dexrazoxane, doxorubicin, cranial radiation (once daily fractionation), cranial radiation (twice-daily fractionation), Intrathecal chemotherapy without radiation
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 18 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
6
States / cities
New Orleans, Louisiana • Lewiston, Maine • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00186875
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoma, Lymphoblastic
Interventions
Etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase, chemotherapy, intrathecal chemotherapy, steroid therapy, Hematopoietic Stem Cell Transplant, Natural Killer (NK) Cell Transplant
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
2
States / cities
San Diego, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 9, 2026, 4:53 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT03571321
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions
Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 9, 2026, 4:53 PM EDT
Not yet recruiting No phase listed Observational

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

NCT07499882
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
Ziconotide
Drug
Lead sponsor
Christian Hospital Northeast Northwest
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 9, 2026, 4:53 PM EDT
Not listed Phase 1 Interventional

Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors

NCT00003073
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
liposomal cytarabine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00109837
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, mitoxantrone, Asparaginase, prednisone, thioguanine, vincristine, radiation therapy, allopurinol, bactrim
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 64 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
78
States / cities
Burbank, California • Maywood, Illinois • Chanute, Kansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 9, 2026, 4:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04501614
View directory record Official record
Conditions
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
Interventions
Ponatinib, Chemotherapy Agents
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 9, 2026, 4:53 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

NCT00002704
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 9, 2026, 4:53 PM EDT